Maynard Um
-
-
-
-
-
-
-
Celcuity reports positive Phase 3 trial results for gedatolisib in breast cancer
-
-
-
-
-
-
-
Increasing unusual option volume: TPG XRX FXY CGNX MRAM CRNC CELC SIMO
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Celcuity Inc (CELC)
-
-
-
-
-
-
-
Wolfe Research: 'We'd be buyers of CELC on any weakness related to the external catalyst'
-
-
-
-
-
-
-
Increasing unusual call option volume: EQG CELC BBD FE CWAN
-
-
-
-
-
-
-
Celcuity increases term loan facility to $500 million
-
-
-
-
-
-
-
Celcuity receives patent extending gedatolisib exclusivity to 2042
-
401,681 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

